IMLINFO: Cross-border network of personalised immunotherapies for non-Hodgkin’s lymphoma

IMLINFO is a cross-border network of personalised immunotherapies for Non-Hodgkin’s Lymphoma (NHL) involving seven organisations located in Spain and France. Its main objective is to determine the efficacy of new immunotherapy treatments through the creation of an NHL repository associated with a three-dimensional (3-D) culture.

IMLINFO is formed by a multidisciplinary team composed of experts in 3-D culture systems, multicellular cultures, as well as in structural characterisation and drug penetrability by advanced microscopy. Similarly, the pharmaceutical company integrated in IMLINFO brings its proven experience in the development of small molecules as innovative immunotherapies already licensed to international pharmaceutical companies. In order to move towards personalised medicine, cross-border cooperation is essential to obtain a large number of NHL patient samples from hospitals in the POCTEFA territory as well as scientific and technological collaboration.

Partner CRCT : Christine Bezombes

For more information : >>>

Start date: 01/01/2018
End date: 31/12/2021

This research programme, funded by the European Regional Development Fund (ERDF), is part of the European Horizon 2020 – POCTEFA : https://www.poctefa.eu

Pin It on Pinterest